Dr. Irene Malaty, from the University of Florida, discusses how to identify patients who may benefit from Vyalev (foscarbidopa/foslevodopa), highlighting key indicators that a patient is ready to transition beyond oral levodopa therapy. She reviews the impact of motor fluctuations, medication burden, and absorption challenges, and explains how continuous subcutaneous levodopa delivery may help address both daytime and overnight symptom control in patients with advanced Parkinson’s disease.
